These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 30689140)
1. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. McNeill AM; Davies G; Kruger E; Kowal S; Reason T; Ejzykowicz F; Hannachi H; Cater N; McLeod E Diabetes Ther; 2019 Apr; 10(2):473-491. PubMed ID: 30689140 [TBL] [Abstract][Full Text] [Related]
2. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Shyangdan DS; Uthman OA; Waugh N BMJ Open; 2016 Feb; 6(2):e009417. PubMed ID: 26911584 [TBL] [Abstract][Full Text] [Related]
3. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials. Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304 [TBL] [Abstract][Full Text] [Related]
4. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. Evans M; Achha S; Neslusan C Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512 [TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939 [TBL] [Abstract][Full Text] [Related]
7. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes. Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649 [TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis. Lautsch D; Alsumali A; McLeod E; Kuang Y; He J; Singh R; Nevo A; Arnet U; Uyei J; Rajpathak S Diabetes Ther; 2021 Jan; 12(1):389-418. PubMed ID: 33313996 [TBL] [Abstract][Full Text] [Related]
9. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986 [TBL] [Abstract][Full Text] [Related]
10. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis]. Tian L; Wang QY; Sun RM; Qi MM; Li YX; Gao X; Zhang LQ; Ma X; Shi H; Yu J; Bai F Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):1000-1011. PubMed ID: 34674438 [No Abstract] [Full Text] [Related]
11. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor. Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151 [TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients. Scheen AJ Diabetes Metab Syndr Obes; 2020; 13():2765-2779. PubMed ID: 32821142 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Sharma R; Wilkinson L; Vrazic H; Popoff E; Lopes S; Kanters S; Druyts E Curr Med Res Opin; 2018 Sep; 34(9):1595-1603. PubMed ID: 29764222 [TBL] [Abstract][Full Text] [Related]
15. A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. Orme M; Fenici P; Lomon ID; Wygant G; Townsend R; Roudaut M Diabetol Metab Syndr; 2014; 6():73. PubMed ID: 25006351 [TBL] [Abstract][Full Text] [Related]
16. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214 [TBL] [Abstract][Full Text] [Related]
17. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524 [TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085 [TBL] [Abstract][Full Text] [Related]
20. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis. Kim YJ; Hwang SD; Lim S Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]